mirtazapine | Mirtazapine Canon tablets coated.pl.ob. 30 mg 30 pcs.
Special Price
$23.00
Regular Price
$34.00
In stock
SKU
BID474448
Release form
film-coated tablets
film-coated tablets
Release form
film-coated tablets
Packing
10 pcs. - blister packs (3) - packs of cardboard.
Indications
Depressive conditions (including anhedonia, psychomotor inhibition, insomnia, early awakening, weight loss, loss of interest in life, suicidal thoughts and mood lability).
Contraindications
Renal and hepatic failure, pregnancy, lactation, hypersensitivity to mirtazapine.
Use during pregnancy and lactation
Contraindicated in pregnancy and lactation.
Special instructions
Use with caution in patients with epilepsy and organic brain damage, with impaired liver and / or kidney function, acute cardiovascular disease, with arterial hypotension, impaired urination due to benign prostatic hyperplasia, with closed-angle diabetes mellitus.
In patients with schizophrenia, mirtazapine can cause increased delirium, hallucinations. In the treatment of the depressive phase of manic-depressive psychosis, this condition can go into the manic phase.
Sudden discontinuation of mirtazapine after prolonged treatment may cause nausea, headache, and poor health.
It should be borne in mind that if symptoms such as fever, sore throat, stomatitis appear during treatment, stop treatment and do a clinical blood test.
If jaundice occurs, mirtazapine should be discontinued.
Do not use concomitantly with MAO inhibitors and within 2 weeks after their withdrawal.
Perhaps the development of drug dependence, withdrawal.
During treatment, patients should refrain from drinking alcohol.
Mirtazapine is not used in children due to the lack of data on the effectiveness and safety of its use in pediatric practice.
Effect on the ability to drive vehicles and control mechanisms
Use with caution in patients whose activities are associated with the need for a high concentration of attention and speed of psychomotor reactions.
Composition of
mirtazapine 45 mg
Dosage and administration of
When administered orally, the effective dose for adults is 15-45 mg / day, preferably 1 time / day before bedtime. The dose is gradually increased to 30-45 mg / day.
The antidepressant effect develops gradually, usually after 2-3 weeks from the start of treatment, however, administration should be continued for another 4-6 months. If no therapeutic effect is observed within 6-8 weeks of treatment, treatment should be discontinued.
The abolition of mirtazapine is carried out gradually.
Side effects
From the side of the central nervous system and peripheral nervous system: drowsiness, lethargy, emotional lability, changes in mentality, agitation, anxiety, apathy, hallucinations, depersonalization, hostility, mania, epileptic seizures, dizziness, vertigo, hyperesthesia, convulsions, tremors, myoclonus, hyperkinesis, hypokinesia.
From the side of hematopoiesis: inhibition of hematopoiesis - granulocytopenia, agranulocytosis, neutropenia, eosinophilia, aplastic anemia, thrombocytopenia.
On the part of the metabolism: a slight increase in appetite and weight gain in isolated cases - edema.
From the cardiovascular system: rarely - orthostatic hypotension.
From the digestive system: nausea, vomiting, constipation, increased appetite, weight gain, dry mouth, thirst, abdominal pain in isolated cases - increased liver transaminases.
From the reproductive system: decreased potency, dysmenorrhea.
Other: skin rashes, urticaria, flu-like syndrome, choking, edematous syndrome, myalgia, back pain, dysuria.
Drug interaction
With the simultaneous use of mirtazapine enhances the sedative effect of benzodiazepine derivatives.
A case of the development of a hypertensive crisis with simultaneous use with clonidine is described.
With simultaneous use with levodopa, a case of the development of severe psychosis with sertraline is described - a case of the development of hypomania.
With simultaneous use with ethanol, it is possible to increase the inhibitory effect of ethanol and ethanol-containing drugs on the central nervous system.
Storage conditions
In dry, protected from light at a temperature not exceeding 25 РC.
Keep out of the reach and sight of children.
Expiration
2 years.
Active ingredient
Mirtazapine
lekarstvennaja form
tablets
Canonfarm, Russia
film-coated tablets
Packing
10 pcs. - blister packs (3) - packs of cardboard.
Indications
Depressive conditions (including anhedonia, psychomotor inhibition, insomnia, early awakening, weight loss, loss of interest in life, suicidal thoughts and mood lability).
Contraindications
Renal and hepatic failure, pregnancy, lactation, hypersensitivity to mirtazapine.
Use during pregnancy and lactation
Contraindicated in pregnancy and lactation.
Special instructions
Use with caution in patients with epilepsy and organic brain damage, with impaired liver and / or kidney function, acute cardiovascular disease, with arterial hypotension, impaired urination due to benign prostatic hyperplasia, with closed-angle diabetes mellitus.
In patients with schizophrenia, mirtazapine can cause increased delirium, hallucinations. In the treatment of the depressive phase of manic-depressive psychosis, this condition can go into the manic phase.
Sudden discontinuation of mirtazapine after prolonged treatment may cause nausea, headache, and poor health.
It should be borne in mind that if symptoms such as fever, sore throat, stomatitis appear during treatment, stop treatment and do a clinical blood test.
If jaundice occurs, mirtazapine should be discontinued.
Do not use concomitantly with MAO inhibitors and within 2 weeks after their withdrawal.
Perhaps the development of drug dependence, withdrawal.
During treatment, patients should refrain from drinking alcohol.
Mirtazapine is not used in children due to the lack of data on the effectiveness and safety of its use in pediatric practice.
Effect on the ability to drive vehicles and control mechanisms
Use with caution in patients whose activities are associated with the need for a high concentration of attention and speed of psychomotor reactions.
Composition of
mirtazapine 45 mg
Dosage and administration of
When administered orally, the effective dose for adults is 15-45 mg / day, preferably 1 time / day before bedtime. The dose is gradually increased to 30-45 mg / day.
The antidepressant effect develops gradually, usually after 2-3 weeks from the start of treatment, however, administration should be continued for another 4-6 months. If no therapeutic effect is observed within 6-8 weeks of treatment, treatment should be discontinued.
The abolition of mirtazapine is carried out gradually.
Side effects
From the side of the central nervous system and peripheral nervous system: drowsiness, lethargy, emotional lability, changes in mentality, agitation, anxiety, apathy, hallucinations, depersonalization, hostility, mania, epileptic seizures, dizziness, vertigo, hyperesthesia, convulsions, tremors, myoclonus, hyperkinesis, hypokinesia.
From the side of hematopoiesis: inhibition of hematopoiesis - granulocytopenia, agranulocytosis, neutropenia, eosinophilia, aplastic anemia, thrombocytopenia.
On the part of the metabolism: a slight increase in appetite and weight gain in isolated cases - edema.
From the cardiovascular system: rarely - orthostatic hypotension.
From the digestive system: nausea, vomiting, constipation, increased appetite, weight gain, dry mouth, thirst, abdominal pain in isolated cases - increased liver transaminases.
From the reproductive system: decreased potency, dysmenorrhea.
Other: skin rashes, urticaria, flu-like syndrome, choking, edematous syndrome, myalgia, back pain, dysuria.
Drug interaction
With the simultaneous use of mirtazapine enhances the sedative effect of benzodiazepine derivatives.
A case of the development of a hypertensive crisis with simultaneous use with clonidine is described.
With simultaneous use with levodopa, a case of the development of severe psychosis with sertraline is described - a case of the development of hypomania.
With simultaneous use with ethanol, it is possible to increase the inhibitory effect of ethanol and ethanol-containing drugs on the central nervous system.
Storage conditions
In dry, protected from light at a temperature not exceeding 25 РC.
Keep out of the reach and sight of children.
Expiration
2 years.
Active ingredient
Mirtazapine
lekarstvennaja form
tablets
Canonfarm, Russia
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review